HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 7 (July)

1. Changes in the risk of death after HIV seroconversion compared with mortality in the general population.
   JAMA, 300(1): 51-9. [Abstract] [Full-text]
2. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels.
   J Infect Dis, 198(2): 241-9. [Abstract] [Full-text]
3. HIV-1 Vif, APOBEC, and intrinsic immunity.
   Retrovirology, 5: 51. [Abstract] [Full-text]
4. Daxx interacts with HIV-1 integrase and inhibits lentiviral gene expression.
   Biochem Biophys Res Commun, 373(2): 241-5. [Abstract] [Full-text]
5. An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children.
   J Allergy Clin Immunol, 122(1): 173-80, 180.e1-2. [Abstract] [Full-text]
6. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
   J Allergy Clin Immunol, 122(1): 22-8. [Abstract] [Full-text]
7. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease.
   J Allergy Clin Immunol, 122(1): 12-9; quiz 20-1. [Abstract] [Full-text]
8. Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.
   J Allergy Clin Immunol, 122(1): 166-72, 172.e1-2. [Abstract] [Full-text]
9. Critical issues in mucosal immunity for HIV-1 vaccine development.
   J Allergy Clin Immunol, 122(1): 3-9; quiz 10-1. [Abstract] [Full-text]
10. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
    Clin Infect Dis, 47(3): 421-4. [Abstract] [Full-text]
11. Effects of early, abrupt weaning on HIV-free survival of children in Zambia.
    N Engl J Med, 359(2): 130-41. [Abstract] [Full-text]
12. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    N Engl J Med, 359(2): 119-29. [Abstract] [Full-text]
13. Imaging the biogenesis of individual HIV-1 virions in live cells.
    Nature, 454(7201): 236-40. [Abstract] [Full-text]
14. Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters.
    AIDS, 22(12): 1515-7. [Abstract] [Full-text]
15. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women?
    AIDS, 22(12): 1503-11. [Abstract] [Full-text]
16. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection.
    AIDS, 22(12): 1487-91. [Abstract] [Full-text]
17. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.
    AIDS, 22(12): 1475-85. [Abstract] [Full-text]
18. Cytomegalovirus and Epstein-Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis.
    AIDS, 22(12): 1453-60. [Abstract] [Full-text]
19. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    AIDS, 22(12): 1425-31. [Abstract] [Full-text]
20. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    AIDS, 22(12): 1417-23. [Abstract] [Full-text]
21. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    AIDS, 22(12): 1389-97. [Abstract] [Full-text]
22. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.
    J Virol, 82(15): 7700-10. [Abstract] [Full-text]
23. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide.
    J Virol, 82(15): 7591-600. [Abstract] [Full-text]
24. Vpx is critical for reverse transcription of the human immunodeficiency virus type 2 genome in macrophages.
    J Virol, 82(15): 7752-6. [Abstract] [Full-text]
25. Compensatory role of human immunodeficiency virus central polypurine tract sequence in kinetically disrupted reverse transcription.
    J Virol, 82(15): 7716-20. [Abstract] [Full-text]
26. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor.
    J Virol, 82(15): 7395-410. [Abstract] [Full-text]
27. Mechanistic studies of a T20-dependent human immunodeficiency virus type 1 variant.
    J Virol, 82(15): 7735-40. [Abstract] [Full-text]
28. Liquid-crystal NMR structure of HIV TAR RNA bound to its SELEX RNA aptamer reveals the origins of the high stability of the complex.
    Proc Natl Acad Sci U S A, 105(27): 9210-5. [Abstract] [Full-text]
29. Candida albicans-induced DC activation partially restricts HIV amplification in DCs and increases DC to T-cell spread of HIV.
    J Acquir Immune Defic Syndr, 48(4): 398-407. [Abstract] [Full-text]
30. Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
    J Acquir Immune Defic Syndr, 48(4): 381-8. [Abstract] [Full-text]
31. CD4 independent binding of HIV gp120 to mannose receptor on human spermatozoa.
    J Acquir Immune Defic Syndr, 48(4): 389-97. [Abstract] [Full-text]
32. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study.
    J Acquir Immune Defic Syndr, 48(4): 491-9. [Abstract] [Full-text]
33. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption.
    J Acquir Immune Defic Syndr, 48(4): 455-9. [Abstract] [Full-text]
34. Efavirenz in human breast milk, mothers', and newborns' plasma.
    J Acquir Immune Defic Syndr, 48(4): 450-4. [Abstract] [Full-text]
35. Insulin-like growth factor-1 and lean body mass in HIV-infected children.
    J Acquir Immune Defic Syndr, 48(4): 437-43. [Abstract] [Full-text]
36. Adherence to antiretrovirals among US women during and after pregnancy.
    J Acquir Immune Defic Syndr, 48(4): 408-17. [Abstract] [Full-text]
37. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.
    J Acquir Immune Defic Syndr, 48(4): 428-36. [Abstract] [Full-text]
38. Vitamin content of breast milk from HIV-1-infected mothers before and after flash-heat treatment.
    J Acquir Immune Defic Syndr, 48(4): 444-9. [Abstract] [Full-text]
39. Burden of depression among impoverished HIV-positive women in Peru.
    J Acquir Immune Defic Syndr, 48(4): 500-4. [Abstract] [Full-text]
40. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
    J Acquir Immune Defic Syndr, 48(4): 468-75. [Abstract] [Full-text]
41. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali.
    J Acquir Immune Defic Syndr, 48(4): 476-84. [Abstract] [Full-text]
42. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.
    J Acquir Immune Defic Syndr, 48(4): 485-90. [Abstract] [Full-text]
43. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.
    J Acquir Immune Defic Syndr, 48(4): 418-27. [Abstract] [Full-text]
44. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.
    Exp Mol Pathol, 85(1): 2-10. [Abstract] [Full-text]
45. The number and function of circulating dendritic cells may limit effector memory CD4+ T-cell responses in HIV patients responding to antiretroviral therapy.
    Clin Immunol, 128(2): 228-37. [Abstract] [Full-text]
46. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations.
    J Am Chem Soc, 130(29): 9492-9. [Abstract] [Full-text]
47. Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area.
    Am J Epidemiol, 168(3): 311-20. [Abstract] [Full-text]
48. Destabilization of the TAR hairpin affects the structure and function of the HIV-1 leader RNA.
    Nucleic Acids Res, 36(13): 4352-63. [Abstract] [Full-text]
49. Role of the HIV gp120 conserved domain 5 in processing and viral entry.
    Biochemistry, 47(30): 7788-95. [Abstract] [Full-text]
50. Simian immunodeficiency virus is susceptible to inhibition by carbohydrate-binding agents in a manner similar to that of HIV: implications for further preclinical drug development.
    Mol Pharmacol, 74(2): 330-7. [Abstract] [Full-text]
51. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    N Engl J Med, 359(4): 355-65. [Abstract] [Full-text]
52. Raltegravir with optimized background therapy for resistant HIV-1 infection.
    N Engl J Med, 359(4): 339-54. [Abstract] [Full-text]
53. Whither or wither microbicides?
    Science, 321(5888): 532-4. [Abstract] [Full-text]
54. Impact of MHC class I diversity on immune control of immunodeficiency virus replication.
    Nat Rev Immunol, 8(8): 619-30. [Abstract] [Full-text]
55. CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics.
    PLoS Pathog, 4(7): e1000109. [Abstract] [Full-text]
56. Herpes simplex virus and HIV-1: deciphering viral synergy.
    Lancet Infect Dis, 8(8): 490-7. [Abstract] [Full-text]
57. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
    Lancet Infect Dis, 8(8): 477-89. [Abstract] [Full-text]
58. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya.
    J Virol, 82(16): 8172-82. [Abstract] [Full-text]
59. The secondary structure of the human immunodeficiency virus type 1 transcript modulates viral splicing and infectivity.
    J Virol, 82(16): 8038-50. [Abstract] [Full-text]
60. Dendritic cells preferentially transfer CXCR4-using human immunodeficiency virus type 1 variants to CD4+ T lymphocytes in trans.
    J Virol, 82(16): 7886-96. [Abstract] [Full-text]
61. Virological consequences of early events following cell-cell contact between human immunodeficiency virus type 1-infected and uninfected CD4+ cells.
    J Virol, 82(16): 7773-89. [Abstract] [Full-text]
62. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
    J Virol, 82(16): 8210-4. [Abstract] [Full-text]
63. A small molecule, Lys-Ala-7-amido-4-methylcoumarin, facilitates RNA dimer maturation of a stem-loop 1 transcript in vitro: structure-activity relationship of the activator.
    Biochemistry, 47(31): 8148-56. [Abstract] [Full-text]
64. Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.
    Virology, 378(1): 58-68. [Abstract] [Full-text]
65. HIV-1 matrix protein repositioning in nucleocapsid region fails to confer virus-like particle assembly.
    Virology, 378(1): 97-104. [Abstract] [Full-text]
66. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys.
    Proc Natl Acad Sci U S A, 105(30): 10489-94. [Abstract] [Full-text]
67. Differential requirements for Alix and ESCRT-III in cytokinesis and HIV-1 release.
    Proc Natl Acad Sci U S A, 105(30): 10541-6. [Abstract] [Full-text]
68. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.
    J Med Virol, 80(9): 1523-9. [Abstract] [Full-text]
69. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation.
    J Med Virol, 80(9): 1507-14. [Abstract] [Full-text]
70. Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling.
    J Neurosci, 28(31): 7788-96. [Abstract] [Full-text]
71. In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression.
    J Acquir Immune Defic Syndr, 48(5): 511-21. [Abstract] [Full-text]
72. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients.
    J Acquir Immune Defic Syndr, 48(5): 522-30. [Abstract] [Full-text]
73. Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
    J Acquir Immune Defic Syndr, 48(5): 572-6. [Abstract] [Full-text]
74. The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection.
    J Acquir Immune Defic Syndr, 48(5): 577-80. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.